Alvotech is a global biopharmaceutical company that is focused on developing and manufacturing biosimilars and biobetters for patients worldwide. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Alvotech is privately held and has a strong focus on research and development, with a goal of bringing high-quality, affordable biosimilars and biobetters to patients in need. The company has a state-of-the-art facility in Reykjavik, which houses its research and development, quality control, and manufacturing operations.
Alvotech's pipeline includes biosimilar and biobetter versions of several high-value biologic drugs, including Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab). The company has several partnerships in place with leading pharmaceutical companies to develop and commercialize its products globally.
Alvotech is committed to providing patients with access to affordable and high-quality biologic drugs, and its biosimilars and biobetters have the potential to transform the lives of patients around the world. The company is well-positioned to become a leading player in the global biosimilar market.
|
